Tesamorelin

Tesamorelin is a modified GHRH analog distinguished from other compounds in the GHRH class by a critical structural addition: a trans-3-hexenoic acid (t-HEA) group conjugated to the N-terminal tyrosine. This modification confers resistance to dipeptidyl peptidase IV (DPP-IV) cleavage—a primary degradation pathway for unmodified GHRH—substantially extending the compound's active window and receptor engagement in preclinical and investigative models.

The full 44-amino acid GHRH sequence is preserved in Tesamorelin (unlike shorter fragments such as Sermorelin or Mod GRF 1-29), which means it retains the complete GHRH receptor activation profile, including downstream cAMP-mediated GH synthesis and release. In published Phase III research studies, Tesamorelin demonstrated statistically significant effects on trunk adiposity and IGF-1 levels, establishing a well-documented investigative pharmacology dataset that gives researchers a reliable reference compound for GH-axis studies.

APEX 100 supplies Tesamorelin as ≥99% HPLC-verified lyophilized powder with a full Certificate of Analysis. Molecular weight ~5,135.86 Da. Soluble in sterile or bacteriostatic water.

For research and laboratory use only. Not for human consumption.

<

p style="